Current Report Filing (8-k)
November 09 2022 - 04:08PM
Edgar (US Regulatory)
0001642380 false --12-31 0001642380
2022-11-03 2022-11-03 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (date of earliest event reported):
November 3, 2022
Oncocyte Corporation
(Exact
name of registrant as specified in its charter)
|
California |
|
1-37648 |
|
27-1041563 |
|
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
15 Cushing
Irvine,
California
92618
(Address
of principal executive offices)
(949)
409-7600
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Exchange
Act:
|
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
|
Common Stock, no par value |
|
OCX |
|
The Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
5.03 |
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal
Year. |
On
and effective as of November 3, 2022, the Board of Directors (the
“Board”) of Oncocyte Corporation (the “Company”) approved and
adopted the Second Amended and Restated Bylaws of the Company (the
“Bylaws”), pursuant to which the Company may appoint a President or
Presidents without requiring that the chief executive officer also
be a President.
The
summary of Bylaws above is not intended to be complete and is
qualified in its entirety by the Bylaws filed herewith as Exhibit
3.1 and incorporated herein by reference.
|
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
ONCOCYTE
CORPORATION |
|
|
|
|
| Date:
November 9, 2022 |
By: |
/s/
Ronald Andrews |
| |
|
Ronald
Andrews |
| |
|
Chief
Executive Officer |
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Feb 2023 to Mar 2023
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Mar 2022 to Mar 2023
